Ik ga even het jaarverslag doorlezen en zal de in mijn ogen interessante pagina's hier posten
De eerste die ik tegenkom is dat ze verwachten dat ze komende jaren nog veel verlies gaan maken. Ze zien hier voorlopig geen verandering in komen. Dus iedereen die hier aan het kijken is of er een break even omzet aan zit te komen en om die reden in MDX zit kan beter een ander aandeel zoeken
We have a history of losses, and we expect to incur net losses for the next several years. We have incurred substantial net losses since our inception, and we expect to continue to incur additional losses for the next several years. For the years ended December 31, 2012, 2013 and 2014, we had a net loss of $11.5 million, $16.2 million and $15.3 million, respectively. From our inception through December 31, 2014, we had an accumulated deficit of $141 million. We expect to continue to incur significant operating expenses and anticipate that our expenses will increase due to costs relating to, among other things: • developing, presenting and publishing additional clinical and economic utility data intended to increase payor coverage and clinician adoption of our current and future solutions; • expansion of our operating capabilities; • expansion of the size and geographic reach of our sales force and our marketing capabilities to commercialize potential future solutions; • employment of additional clinical, quality control, scientific, customer service, laboratory, billing and reimbursement and management personnel; and • employment of operational, financial, accounting and information systems personnel, consistent with expanding our operations and our status as a newly public company following this offering; • researching, developing, validating and commercializing potential future diagnostic solutions, including our prostate and bladder cancer solutions currently in development; and • maintenance, expansion and protection of our intellectual property portfolio and trade secrets.
Even if we achieve significant revenues, we may not become profitable, and even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain consistently profitable could adversely affect the market price of our common stock and could significantly impair our ability to raise capital, expand our business or continue to pursue our growth strategy. For a detailed discussion of our financial condition and results of operations, see “Management’s Discussion and Analysis”.